Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma

NCT04185350 · Unknown status

Last updated 2026-05-28

This clinical trial tests a new imaging method using a radioactive tracer to detect insulinomas in adults with suspected pancreatic tumors.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Early Phase 1 First exploratory testing in people.

Type Interventional (clinical trial)

Design open-label (no blinding) diagnostic study

Participants 60 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2019-05 · est. completion 2020-05

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT04185350 ↗

Description as written by the study sponsor.

Glucagon-like peptide-1 receptor (GLP-1R) is a kind of G protein coupled receptor which regulate the insulin secretion and serves as potential target in the diagnosis of functional pancreas neuroendocrine tumor. The aim of this study was the clinical evaluation of a potential GLP-1R targeted tracer 68Ga-NOTA-MAL-Cys39-exendin-4 for the detection of insulinoma.

Treatments tested

68Ga-NOTA-MAL-Cys39-exendin-4 Drug

After 68Ga-NOTA-MAL-Cys39-exendin-4 injection, the patient drank 300-500ml of water and urinated before the PET/CT scans.

Main thing measured	Standardized uptake value
Sponsor	Nanjing First Hospital, Nanjing Medical University
Conditions studied	Insulinoma
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04185350 ↗